A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
| Status: | Completed |
|---|---|
| Conditions: | Gastrointestinal |
| Therapuetic Areas: | Gastroenterology |
| Healthy: | No |
| Age Range: | 21 - 75 |
| Updated: | 1/21/2018 |
| Start Date: | May 8, 2015 |
| End Date: | June 19, 2017 |
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Sub-study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Adults With Non-alcoholic Steatohepatitis
The purpose of this sub-study of MB130-045 is to determine the pharmacokinetic effects,
pharmacodynamic effects, efficacy and safety of BMS-986036 20 mg QD in subjects with
Non-alcoholic Steatohepatitis (NASH)
pharmacodynamic effects, efficacy and safety of BMS-986036 20 mg QD in subjects with
Non-alcoholic Steatohepatitis (NASH)
For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com
Inclusion Criteria:
- Male or female between 21 and 75 years old
- Body Mass Index (BMI) of 25 or more
Exclusion Criteria:
- Chronic Liver disease other than NASH
- Uncontrolled diabetes
- Any major surgery within 6 weeks of screening
- Unable to self-administer under the skin injections
- Any bone trauma, fracture or bone surgery within 8 weeks of screening
We found this trial at
2
sites
Click here to add this to my saved trials
Thomas Jefferson University Hospital Our hospitals in Center City Philadelphia share a 13-acre campus with...
Click here to add this to my saved trials